Evidence status: MASSACHUSETTS-PUBLISHED CLINICAL GUIDANCE WITH AN EXPRESS DISCLAIMER. Massachusetts hosts 2023 provider guidance on opioid tapering that directly addresses opioid contracts and treatment agreements. The Department of Industrial Accidents states that the recommendations are those of the authors and are not official DIA or Health Care Services Board policy.

Contract effectiveness

The guidance states that evidence for signed opioid-prescribing or tapering contracts is limited and that such contracts may not reliably improve health or discourage misuse.

Coercion and stigma concerns

The guidance warns that patients may feel coerced into signing an agreement in order to continue access to pain medication and that contracts can diminish trust or increase stigma for chronic-pain patients.

Alternative treatment-plan approach

The guidance suggests considering a treatment-plan document that is not signed instead of a contract. If a contract is used, it recommends including provider responsibilities as well as patient responsibilities.

Comprehension and fairness

The guidance recommends ensuring that the patient understands the agreement, providing a copy, and reviewing it regularly. It also cautions that literacy and other barriers may affect a patient’s ability to understand and comply with contract terms.

No abandonment for agreement violation

The guidance states that abandonment must not be a consequence of contract violation and urges clinicians to plan in advance how to respond when a patient refuses to sign, violates a contract, or does not adhere to a treatment plan.

Important legal distinction

This guidance does not repeal M.G.L. c.94C §18A or other binding rules. It is useful as a Massachusetts-published counterweight showing that contract use and enforcement should not be treated mechanically or as a substitute for individualized clinical judgment.

Source

• Massachusetts — Provider Guidance and Worker Fact Sheet for Opioid Tapering
• Provider Guidance for Tapering Opioids

Reviewed: October 4, 2026.

Evidence boundary: Massachusetts expressly states that this 2023 guidance is not official DIA/HCSB policy and is not incorporated into workers’ compensation treatment guidelines.